Nari Yun
Chief Development Officer GI Innovation
Nari Yun is Executive Vice President and Chief Development Officer at GI Innovation, a clinical-stage biotechnology company focused on next-generation immuno-oncology therapies. She leads global clinical strategy and development, and partnering efforts across immunocytokines and combination immunotherapies.
Seminars
Thursday 11th June 2026
Reshaping the Patient T-Cell Landscape: Overcoming T-Cell Engager Limitations Through Cytokine Combination Strategies
3:00 pm
- Examining key limitations of current T-cell engager therapies, including T-cell exhaustion, suboptimal activation, and durability challenges in solid tumors, and where rational combination strategies are emerging as a solution
- Discussing the scientific rationale for combining T-cell engagers with immunocytokines to reshape the tumor microenvironment and enhance T-cell expansion, activation, and persistence
- Exploring translational and clinical development considerations for advancing cytokine + TCE combinations into phase 2 studies, including biomarker strategy and anticipated indicators of synergy
